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Griscelli syndrome (GS), a rare autosomal recessive disorder, is characterized by partial albinism, along with
immunologic abnormalities or severe neurological impairment or both. Mutations in one of two different genes
on chromosome 15q can cause the different subtypes of GS. Most patients with GS display the hemophagocytic
syndrome and have mutations in RAB27A, which codes for a small GTPase. Two patients with neurological
involvement have mutations inMYO5A, which codes for an actin-basedmolecular motor. TheRAB27A andMYO5A
gene products interact with each other and function in vesicle trafficking. We report the molecular basis of GS in
a Muslim Arab kindred whose members have extremely variable neurological involvement, along with the hemo-
phagocytic syndrome and immunologic abnormalities. The patients have normal MYO5A genes but exhibit a
homozygous 67.5-kb deletion that eliminates RAB27A mRNA and immunocytofluorescence-detectable protein.We
also describe the molecular organization of RAB27A and a multiplex polymerase chain reaction assay for the
founder deletion in this kindred. Finally, we propose that all patients with GS have RAB27A mutations and
immunologic abnormalities that sometimes result in secondary neurological involvement. The two patients described
elsewhere who have MYO5A mutations and neurological complications but no immunologic defects may not have
GS but instead may have Elejalde syndrome, a condition characterized by mild hypopigmentation and severe,
primary neurological abnormalities.
Griscelli syndrome (GS [MIM 214450]) is a rare auto-
somal recessive disorder characterized by pigmentary di-
lution of the skin, due to abnormal melanosomal trans-
port, and by silvery gray hair, due to pigment clumping
in hair shafts. Most patients develop the hemophagocytic
syndrome, which is characterized by uncontrolled acti-
vation of T lymphocytes and macrophages and which
leads to death if not treated by bone marrow transplan-
tation (BMT). Some patients show severe neurological
impairment early in life, with or without apparent im-
mune abnormalities (Griscelli et al. 1978; Hurvitz et al.
1993; Klein et al. 1994; Menasche et al. 2000).
Recently, GS was reported to consist of two different
subtypes, resulting from defects in two separate genes,
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MYO5A and RAB27A (Pastural et al. 2000). Myosin
5a, the product ofMYO5A on chromosome 15q21 (Pas-
tural et al. 1997), is an unconventional myosin motor
protein that moves along actin filaments and functions
in intracellular vesicle transport (Metha et al. 1999).
Among humans with GS, one patient exhibited a mis-
sense change in MYO5A (Pastural et al. 1997), but this
was later shown to be a polymorphism (Lambert et al.
2000). Both remaining reported patients who had GS
with mutatedMYO5A (patients P3 [Pastural et al. 1997]
and P8 [Pastural et al. 2000]) exhibited primarily neu-
rological impairment without immune defects.
A second genetic cause of GS was discovered because
a large number of patients did not show a mutation in
MYO5A. Linkage analysis indicated the existence of
this second locus in the q21 region of chromosome 15
(Pastural et al. 2000), and physical mapping and mu-
tation analysis identified the RAB27A gene, !1.6 cM
fromMYO5A (Menasche et al. 2000). The rab27a pro-
tein is a small GTPase that functions in the targeting
and the fusion of transport vesicles with their appro-
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Figure 1 Northern blot analysis of MYO5A and RAB27A expression. Total RNA extracts (20 mg) of two normal individuals (N-1, N-
2) and of patient IV with Griscelli syndrome (P) were separated on a formaldehyde gel, were blotted to a nylon membrane, and were hybridized
with a [32P]-dCTP–labeled DNA probe to MYO5A (A) and to RAB27A (B). Both blots were also labeled with a b-actin probe (lower panels),
which served as a control for the amount of loaded RNA. The patient has abundant MYO5A RNA and no RAB27A RNA.
priate acceptor membranes. Like other rab proteins,
rab27a requires geranylgeranylation of two consensus
C-terminal cysteine residues in order to be anchored to
membranes. Truncation of the carboxy-terminal part
of rab27a would render it inactive (Kinsella and Mal-
tese 1992; Chen et al. 1997; Novick and Zerial 1997;
Pfeffer et al. 2001). To date, all patients with GS with
mutations in RAB27A have developed the hemophag-
ocytic syndrome.
In accordance with the paradigm that patients with
GS with neurological involvement have mutations in
MYO5A and that those with the hemophagocytic syn-
drome have mutations in RAB27A (Pastural et al. 2000;
Westbroek et al. 2001), the kindred with GS reported
by Hurvitz et al. (1993) was expected to exhibitMYO5A
mutations. Results of the present study show that mem-
bers of this kindred have, instead, a large deletion in
RAB27A. We suggest that the neurological involvement
in these patients with GS occurs secondarily to the hemo-
phagocytic syndrome and that patients with primary
CNS complications and MYO5A mutations have a re-
lated disorder, namely, Elejalde syndrome.
The patient described in the present study was part of
a highly consanguineous Muslim Arab family, in which
Griscelli syndrome was diagnosed (Hurvitz et al. 1993).
This family includes four affected children: a brother (pa-
tient IV, our proband) and a sister (patient I) in one family
and their two female first cousins (patients II and III). All
four individuals died in childhood, at ages 11.5 years, 10
mo, 6 years, and 2 years, respectively. All had silvery hair.
Skin biopsies revealed normal numbers of melanocytes
containing normally sized melanin granules; it was sug-
gested that no melanosomes were transferred to the sur-
rounding keratinocytes (Hurvitz et al. 1993). Patients I,
II, and III presented with recurrent vomiting; patient I had
an acute febrile illness, and patient III presented with leth-
argy. All three patients deteriorated neurologically after
their initial presentation, as indicated by regression of
mental and physical function. The clinical course of pa-
tient IV was characterized by periodic episodes of sei-
zures, from the age of 1 age, and by mild cognitive delay.
At the age of 2 years 10 mo, patient IV experienced an
episode similar to the accelerated phase described by
Griscelli et al. (1978) and recovered completely. He was
well and had no recurrent infections, and his neurolog-
ical status was stable until age 8 years. He was not mon-
itored between the ages of 8 years and 10.5 years, after
which he was repeatedly admitted to a local hospital
because of prolonged fever, severe hepatosplenomegaly,
and pancytopenia. His condition deteriorated, and he
developed ascites, generalized edema, and jaundice and
died at the age of 11.5 years.
Genomic DNA and RNA were isolated from cultured
skin fibroblasts of patient IV. The entire coding region of
MYO5A cDNA (GenBank accession number U90942) of
the patient and several normal control individuals was
amplified by PCR in eight overlapping fragments (primer
sequences available upon request), followed by direct se-
quencing. This revealed no MYO5A cDNA mutations in
the patient. We then performed a northern blot, using a
MYO5A tail region fragment (nt 3735–4628) as the hy-
bridization probe. This blot showed a normal size and
amount of each of the three alternatively splicedfibroblast
MYO5A transcripts (12 kb, 7 kb, and 5.5 kb) in patient
IV (fig. 1A). The increased intensity of theMYO5A bands
in patient IV corresponds to the increased b-actin signal,
indicating that more of the patient’s RNA was loaded on
the gel.
Next, we attempted to amplify RAB27A, using cDNA
from patient IV and from normal control subjects as
template (forward primer 5′-TGAAGCATTGGTAACT-
CCAG-3′ and reverse primer 5′-TCTCACTGTGCCAT-
GTATCAA-3′). No PCR product was amplified for the
patient (fig. 2). Subsequent northern blot analysis with
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Figure 2 cDNA amplification of RAB27A and the adjacent
genes, LOC51187 and PIGB. PCR products of portions ofLOC51187
(lane 1), RAB27A (lane 2), and PIGB (lane 3) obtained by use of
cDNA from an unaffected control subject (left) and patient IV (right).
The patient has normal amplification of LOC51187 and PIGB but
no signal for RAB27A.
a RAB27A cDNA hybridization probe (GenBank ac-
cession number U38654; nt 155–990) showed no ex-
pression of the 3.5-kb major transcript of RAB27A in
fibroblasts from the patient (fig. 1B).
Genomic DNA of the patient and several control in-
dividuals was then PCR amplified for each exon of the
RAB27A gene (GenBank accession number AF443871),
using primer sequences for exons 2–6 as reported by Tol-
machova et al. (1999). For amplification of the exon 1
region, we used forward primer 5′-GTGCCATATGACA-
AACAGCTG-3′ and reverse primer 5′-CTCCGTGGTCA-
CTGAAAATGC-3′. All six exons of RAB27A (Tolma-
chova et al. 1999) were successfully amplified by use
of control gDNA. However, amplification of the pa-
tient’s genomic DNA yielded product only for exon 6,
while exons 1–5 could not be amplified.
Amplification of the patient’s cDNA for genes neigh-
boring RAB27A (i.e., PIGB and LOC51187) yielded the
expected bands (fig. 2). For PIGB (GenBank accession
number NM_004855) amplification, the forward primer
was 5′-CGAAAGAGAAAGTCTACCTTGTAC-3′, and
the reverse primer was 5′-CAAAGGTGTCCACAGA-
ATGACAGC-3′. For LOC51187 (GenBank accession
number XM_046136) amplification, the forward prim-
er was 5′-CATCTATCCTGGACACGGCATG-3′, and
the reverse primer was 5′-GAGCATCTTCCATGTCCA-
CATC-3′. These results pointed to a large deletion ex-
tending from its 5′ breakpoint in the region between
PIGB and exon 1 of RAB27A (∼49-kb) to its 3′ break-
point in intron 5 of the RAB27A gene (∼18 kb).
To identify the exact deletion breakpoints, we first
determined the organization of the RAB27A gene, in-
cluding the complete intronic sequences, whichwere pre-
viously unreported. Two overlapping BACs (GenBank
accession numbers AC011912 and AC018926) covered
the entire RAB27A region. Using these BACs and the
intron/exon boundaries reported by Tolmachova et al.
(1999), we identified the completeRAB27A gDNA (sub-
mitted to GenBank as accession number AF443871),
which spans ∼86.6 kb of DNA. We then designed PCR
primers to amplify short fragments (∼200–300 bp) at
intervals of ∼3 kb throughout the region of the predicted
RAB27A deletion, and the breakpoint locations were
narrowed until we were able to amplify a fragment en-
compassing the breakpoints. The sequencing of this frag-
ment revealed a PCR product that lacked 67,536 bp,
including all of exons 1–5 and the predicted gene-pro-
moter region. A 6-bp sequence repeat on each end of
the deletion exists only once in the affected individual
(fig. 3).
To detect the presence or absence of the 67.5-kb de-
letion (fig. 3), a multiplex PCR amplification assay was
designed (fig. 3). We used two primer sets in a standard
PCR amplification with an annealing temperature of
58C. The primer set flanking the deletion resulted in a
656-bp fragment (forward primer 5′-GGACAGTGTAT-
GCTTCCTTTCG-3′ and reverse primer 5′-GGGAGTC-
CTGCAATTGAATTCAG-3′), and the primer set within
the deleted area yielded a 439-bp fragment (forward
primer 5′-CTGATGCTTTGAAAGCATTATG-3′ and re-
verse primer 5′-GCATTGTCAATGGATCCTAC-3′).
Multiplex PCR screening of patient IV’s parents and
an aunt who had two affected children (patients I and II)
confirmed that all three were carriers of the 67.5-kb de-
letion (fig. 3). To screen for the presence of the 67.5-kb
deletion in the Palestinian population, 86 anonymous
samples of Palestinian origin were obtained from the Na-
tional Laboratory for the Genetics of Israeli Populations
at Tel Aviv University. None of these samples revealed the
deletion.
Immunocytofluorescence studies were performed to
show the presence and distribution of the RAB27A pro-
tein in the fibroblasts of patient IV and normal unaffect-
ed control subjects (fig. 4). Fibroblasts were grown on
glass coverslips and were fixed for 10 min in 2% for-
maldehyde in PBS. The cells were then incubated for 1 h
with mouse monoclonal antibodies to RAB27A (Trans-
duction Laboratories) that were diluted in PBS, 0.2% sap-
onin (wt/vol), and 0.1% BSA (wt/vol) and were washed
with PBS. The cells were then incubated for 45 min with
FITC-conjugated donkey anti-mouse secondary anti-
bodies (Jackson Immunoresearch), also diluted in PBS/
saponin/BSA. After the cells were washed a second time
in PBS, coverslips were mounted onto glass slides with
Fluoromont G (Southern Biotechnology Associates).Mi-
croscopy was performed on a Zeiss Axioscop-20 with
a FITC filter (Carl Zeiss, Inc.) Normal fibroblasts
showed a distinct punctated distribution of the rab27a
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Figure 3 Structure of the RAB27A deletion and multiplex PCR amplification assay for its presence or absence. A, Schematic basis of the
67,536-bp deletion. The deletion (shaded line) contains exons 1–5 (black and crossed boxes), as well as the predicted promoter region, and is
flanked by normal sequence. Intron sizes and locations of the start and stop codons are shown above the gene, and exon sizes are shown below.
B, The deletion breakpoint occurs somewhere within the 6-bp region shared at either end of the deletion. PCR amplification across the deletion
yields a 656-bp fragment. Two primers within the deleted area (diamond-headed arrows) are used to amplify the DNA of alleles lacking the
deletion; the product is a 439-bp fragment. C, Multiplex PCR in the affected family. PCR amplification products indicate the presence (656-
bp fragment) or absence (439-bp fragment) of the 67,536-bp deletion. Lane 1,molecular weight markers; lane 2, father of patient IV, heterozygous
for the deletion; lane 3, patient IV, homozygous for the deletion; lane 4, mother of patient IV, heterozygous for the deletion; lane 5, aunt of
patient IV, heterozygous for the deletion; lane 6, normal control, lacking the deletion; lane 7, no-DNA control.
protein throughout the cell, similar to the distribution
pattern in melanocytes reported by Hume et al. (2001).
In contrast, there was no visible rab27a signal in fibro-
blasts from the patient (fig. 4).
Three different rare, autosomal recessive disorders are
characterized by hypopigmentation and silvery hair in
infancy or early childhood (table 1). Chediak-Higashi
syndrome (CHS [MIM 214500]) presents with variable
hypopigmentation of the skin, hair, and eyes, a bleeding
diathesis due to platelet-storage-pool deficiency, slow-
ly progressive neurological dysfunction, and severe im-
munodeficiency (Introne et al. 1999; Ward et al. 2000).
CHS cells show giant lysosomes, melanosomes, lytic
granules, and azurophilic granules (Kjeldsen et al. 1998;
Ward et al. 2000). Platelet-dense granules are absent or
reduced in number (Rendu et al. 1983). The gene re-
sponsible for CHS, LYST, encodes a cytoplasmic protein
of ∼430 kD (Barbosa et al. 1996; Nagle et al. 1996).
Expression studies of LYST suggest a role in membrane
fusion or fission events (Perou et al. 1997), and the large
size of the LYST protein and its cytoplasmic location
also argue for a role in vesicle transport. The beigemouse
is the murine counterpart of CHS (Barbosa et al. 1996;
Perou et al. 1996).
Elejalde syndrome (ES [MIM 256710]), also called
“neuroectodermal melanolysosomal disease,” is charac-
terized by silvery hair, pigment abnormalities, and severe
dysfunction of the CNS, with seizures, severe hypotonia,
and mental retardation (Elejalde et al. 1979; Sanal et al.
2000). Patients with ES do not manifest the hemophag-
ocytic syndrome or immunologic defects. Large granules
of melanin are unevenly distributed in hair shafts, and
abnormal melanosomes may occur in melanocytes, along
with inclusion bodies in fibroblasts (Duran-McKinster et
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Figure 4 Intracellular rab27a distribution detected by indirect immunocytofluorescence. Normal (A) and patient (B) fibroblasts were
grown on coverslips and were fixed and permeabilized before incubation with rab27a antibodies. FITC-conjugated secondary antibodies were
used for fluorescent labeling. Rab27a shows a distinct punctated distribution throughout the normal fibroblasts. The patient’s fibroblasts, lacking
rab27a, show only background fluorescence.
al. 2000). No gene has been reported to be associated
with ES, nor has any mouse model been identified.
Patients with GS exhibit the accelerated phase and
immunologic dysfunction seen in CHS but not in ES. In
addition, some patients with GS have neurological in-
volvement that shows extremely variable expression and
severity. Two genes, RAB27A and MYO5A, which are
separated by only ∼3 mB on chromosome 15, have been
reported to cause GS. In mice, Myo5a mutations cor-
respond with the dilute phenotype (Mercer et al. 1991),
whereas Rab27a mutations cause the ashen phenotype
(Wilson et al. 2000). These two mouse models, along
with leaden (which has mutations in melanophilin [Ma-
tesic et al. 2001]), provide a unique system for studying
vesicle transport in mammals. All threemice have a light-
ened coat color because of defects in pigment granule
transport (Swank et al. 1998), and all three are sup-
pressed by the semidominant dilute-suppressor (dsu)
(Moore et al. 1988). Genetic evidence indicates that the
gene products of dilute, ashen, and leaden function in
the same or overlapping pathways, and molecular and
cell-biological studies show that they interact in effect-
ing melanosome trafficking in the distal region of me-
lanocyte dendrites (Wu et al. 2001; Hume et al. 2002;
Provance et al. 2002).
It has been reported—and accepted by the medical
community—that patients who have GS with immu-
nologic defects have RAB27A mutations and that those
with neurological involvement have MYO5A mutations
(Pastural et al. 2000; Westbroek et al. 2001). We present
an alternative explanation. Specifically, we propose that
all patients with RAB27A mutations have GS and that
neurological complications in these individuals occur
secondarily to lymphocytic and histiocytic infiltration of
the brain (Gogus et al. 1995). Patients with MYO5A
mutations, then, have ES with primary neurological in-
volvement, which occurs early in life and in the absence
of any signs of the hemophagocytic syndrome.
Several lines of evidence support this thesis. First, the
original report of MYO5A mutations in GS provides in-
formation on only two patients. The first of these, des-
ignated patient 2, had anR1246C substitutionwhich later
proved to be a polymorphism (Lambert et al. 2000). The
second, designated patient 3, was homozygous for a non-
sense mutation inMYO5A, an observation that predicted
a truncated protein lacking 1,087 amino acids. However,
this patient was described by the authors as having “a
severe neurological disorder, similar to the neuroectoder-
mal melanolysosomal disease described by Elejalde et al.”
(Pastural et al. 1997, p. 290). There was no history of
the hemophagocytic syndrome or of immunologic defects
in patient 3, who most likely had ES, not GS.
Second, the initial linkage studies that identified
MYO5A as a candidate GS-causing gene were mislead-
ing because of the extremely close proximity ofRAB27A
to MYO5A on chromosome 15. In fact, the majority of
the patients with GS who were used to identifyMYO5A
as a GS-causing gene actually had RAB27A mutations.
At the same time, patients with MYO5A mutations
would not disrupt the linkage analysis, so their diagnosis
of GS was not questioned. However, these individuals
may, in fact, have had ES.
Third, the only other patient (P8) found to have mu-
tations inMYO5A had a clinical presentation consistent
with ES and not with GS (Pastural et al. 2000). The
child had profound CNS deficits but no immunologic
problems and no evidence of hemophagocytic syndrome.
Fourth, the expression patterns of RAB27A and
MYO5A are consistent with the clinical phenotypes of
GS and ES, respectively. RAB27A is not expressed in
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Table 1
Syndromes That Involve Silvery Hair
Characteristic GS ES Chediak-Higashi
Inheritance Autosomal recessive Autosomal recessive Autosomal recessive
Hair color Silvery/metallic Silvery/metallic Silvery/metallic
Age at onset Infancy/early childhood Infancy/early childhood Infancy/early childhood
Skin pigment dilution   
Eye pigment dilution / / 
Accelerated phase   
Immune defects   
Giant granules   
Neurological involvement   
No. of patients reported 140 110 ∼200
Gene RAB27A MYO5A? LYST
Mouse model dilute ashen beige
Bleeding diathesis   
Treatment BMT  BMT
NOTE.— p present;  p absent; / p may or may not be present;  p a significant feature of
disease; and  p the primary characteristic of disease.
brain tissue, in keeping with the lack of primary neu-
rological abnormalities in GS. In addition, rab27a-de-
ficient T cells exhibit reduced cytotoxity and cytolytic
granule exocytosis required for immune homeostasis
(Menasche et al. 2000; Stinchcombe et al. 2001), con-
sistent with the occurrence of the hemophagocytic syn-
drome of GS. In contrast, some splice products of
MYO5A are expressed in brain tissue (Huang et al.
1998; Lambert et al. 1998), and those that are expressed
in brain tissue may not interact with rab27a (Wu et al.
2002).
Finally, the molecular analysis of patient IV and his
family is consistent with our proposal. Because of his
neurological involvement, patient IV was expected to
have mutations in MYO5A. However, the neurological
symptoms of the affected kindred varied extensively in
age at onset and rate of progression. Furthermore, the
hemophagocytic syndrome antedated the neurological
complications, so histiocytic and lymphocytic invasion
could have caused the CNS involvement. Indeed, the
MYO5A gene was normal in sequence and expression
in our patient, who instead exhibited a large homozy-
gous deletion in RAB27A. We eliminated the possibility
of a contiguous gene syndrome by showing normal ex-
pression of the flanking genes, PIGB and LOC51187,
and we conclude that our patient has genuine GS due
to a RAB27A mutation.
The identification of the breakpoints of the large de-
letion present in the family of patient IV has provided
a useful tool for genetic counseling of this kindred. In
addition, we are now able to screen for the mutation
among unaffected individuals. That the mutation was
absent in 86 anonymous Palestinian individuals is not
surprising. Although a low carrier frequency for the mu-
tation would produce this result, it can also be explained
by the marriage practices of the isolated kindreds that
constitute the Palestinian Arab world. High rates of con-
sanguinity and the rarity of interfamily marriage prevent
the spread of genetic variants through the population,
causing unequal distribution of many autosomal reces-
sive disorders (Zlotogora 1997; Zlotogora et al. 2000).
As more patients with GS or ES are studied at the
molecular level, the clinical and genetic distinctions be-
tween these two entities will be resolved. Because pre-
vention of the hemophagocytic syndrome by BMT may
be lifesaving for patients with GS and an unnecessary
risk for patients with ES, the distinction is critical. We
suggest that patients with MYO5A defects not be as-
signed the diagnosis of GS at this time.
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